ZipBio
ZipBio compresses biological design cycles to accelerate development of gene therapies and biologics for therapeutic partners. The company uses a proprietary AI platform and machine learning models combined with protein engineering, molecular materials and synthetic self-assembly techniques to design and optimize biologics. ZipBio operates as a biotechnology company working with research institutions and biopharma partners to translate designs into therapeutic candidates. Its technology stack spans computational protein design, ML-driven discovery, and molecular materials engineering to de-risk early-stage therapeutic development.
ZipBio
ZipBio compresses biological design cycles to accelerate development of gene therapies and biologics for therapeutic partners. The company uses a proprietary AI platform and machine learning models combined with protein engineering, molecular materials and synthetic self-assembly techniques to design and optimize biologics. ZipBio operates as a biotechnology company working with research institutions and biopharma partners to translate designs into therapeutic candidates. Its technology stack spans computational protein design, ML-driven discovery, and molecular materials engineering to de-risk early-stage therapeutic development.
TL;DR
Headquarters: Seattle, Washington
Founded: 2023
Focus: Generative AI-driven de novo protein design for compact, multispecific therapeutics and gene/vectorizable therapies
Tech: Proprietary COMPACT platform, ML-driven discovery, computational protein design
Funding: Seed (investors include NFX, MoreVC); total disclosed funding reported as $4,000,000
Company Overview
Problem Domain
Accelerating early-stage discovery and design of protein therapeutics and gene therapies to address hard-to-treat indications (initial focus on ophthalmology).
Founded
2023
Industry
Biotechnology
Tech Stack
Funding Track Record
Seed round listed with investors NFX and MoreVC; specific round amount not disclosed in provided evidence
Investor Signal
“Backed by early-stage venture investors including NFX and MoreVC”